AstraZeneca Pharma opened at ₹5,919.00, in line with its previous close of ₹5,919.00. During today's session, the stock has traded between ₹5,790.50 and ₹5,926.00, with an average traded price of ₹5,853.60. It is currently showing a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in AstraZeneca Pharma is now worth
₹ 18,581.00
giving a profit of
₹ 8,581.00 (85.81%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-41.50 (-0.70%)
Day High
₹5,926.00
Day Low
₹5,790.50
Day Open
₹5,919.00
Prev Close
₹5,919.00
Volume
43,240
Value Traded
₹25.31 Cr
1W Return
-0.53%
1M Return
-13.11%
3M Return
-27.59%
6M Return
-29.18%
1Y Return
-36.54%
Market Cap (₹ Cr.)
14,694
PE Ratio
87.30
PB Ratio
16.96
Dividend Yield
0.61%
ROE
21.49%
ROCE
25.48%
Book Value (₹)
349.12
Face Value (₹)
2.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-0.53%
6 Week
-
1 Month
-13.11%
3 Month
-27.59%
9 Month
-28.45%
No data available.
AstraZeneca Pharma fined ₹2.38 lakh for delay in filing Form MR-2
AstraZeneca Pharma India Ltd fined ₹1.88 lakh for late Form MR-2 filing. Erstwhile officers penalised ₹50,000 each for default. Delay caused by MCA portal glitch marking DIN as inactive. Order received from ROC Bengaluru on September 17, 2026.
25 days agoAstraZeneca Pharma India accepts resignation of Dr. Sandeep Arora
Dr. Sandeep Arora resigned as Director – Medical Affairs effective September 15, 2026. He led medical affairs for the Biopharmaceutical and Rare Disease Business Units. The company disclosed the change under SEBI Listing Regulations Regulation 30. AstraZeneca Pharma India is seeking a suitable replacement for the role.
28 days agoAstraZeneca Pharma India receives ESG rating of 64 for FY26
Crisil ESG Ratings assigned an ESG score of 64 to AstraZeneca Pharma India Ltd. The rating covers fiscal year 2026 and relies on publicly available information. The assessment was conducted independently without engagement from the company. Disclosure was filed under Regulation 30 of SEBI LODR regulations on September 2, 2026.
1mo agoDelhi High Court stays NPPA overcharging notice against AstraZeneca until 2027
Delhi High Court stayed NPPA demand notice on Betaloc-50 overcharging until February 10, 2027. Regulator alleged overcharging during June-July 2016 due to non-implementation of revised ceiling prices. Company must deposit 15% of the demanded amount with the court registrar as a condition for the stay. Case relates to notifications from March and June 2016 under DPCO 2013.
1mo agoAstraZeneca Pharma India discloses Crisil ESG rating of 57
AstraZeneca Pharma India received an ESG rating of 57 from Crisil ESG Ratings. The rating was assigned on August 24, 2026, based on public information. The company did not engage Crisil for the independent assessment. Disclosure was made to BSE and NSE under SEBI Regulation 30.
1mo agoAstraZeneca Pharma India schedules virtual investor meeting on Aug 26
AstraZeneca Pharma India Limited schedules a virtual one-on-one meeting with an institutional investor on August 26, 2026. The intimation was filed with BSE and NSE on August 21, 2026, pursuant to SEBI Regulation 30. The meeting date is subject to change based on exigencies from the company or the investor.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in AstraZeneca Pharma is now worth
₹ 18,581.00
giving a profit of
₹ 8,581.00 (85.81%)
Note: Past profits do not guarantee future returns.
